Institutional Owners141 (141 N-Q Owners)

Institutional Stock Ownership and Shareholders

STANDARD INDUSTRIES LTD. (NSE:SIL) has 141 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .

STANDARD INDUSTRIES LTD. (NSE:SIL) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-02-28 N-Q Seasons Series Trust (see advisory)
2017-11-22 N-Q Western Asset Premier Bond Fund (see advisory)
2018-01-26 N-Q Valic Co Ii (see advisory)
2017-09-28 N-Q Mainstay Funds (see advisory)
2018-02-28 N-Q Timothy Plan (see advisory)
2017-10-27 N-Q Prudential Short Duration High Yield Fund, Inc. (see advisory)
2017-09-29 N-Q Ishares U.s. Etf Trust (see advisory)
2017-09-27 N-Q American Century Capital Portfolios Inc (see advisory)
2017-12-27 N-Q Pioneer Series Trust Iv (see advisory)
2017-09-28 N-Q Prudential Investment Portfolios 16 (see advisory)
2017-12-29 N-Q American Beacon Funds (see advisory)
2017-11-29 N-Q Aim Variable Insurance Funds (invesco Variable Insurance Funds) (see advisory)
2018-02-27 N-Q Pioneer Series Trust X (see advisory)
2017-09-28 N-Q Mfs Special Value Trust (see advisory)
2017-09-29 N-Q Ishares Trust (see advisory)
2018-02-26 N-Q Alliancebernstein Global High Income Fund Inc (see advisory)
2017-11-29 N-Q Vanguard Variable Insurance Funds (see advisory)
2017-11-29 N-Q First Investors Life Series Funds (see advisory)
2017-09-29 N-Q Eaton Vance Series Trust Ii (see advisory)
2018-01-29 N-Q Aim Investment Securities Funds (invesco Investment Securities Funds) (see advisory)
2017-10-30 N-Q Delaware Investments Dividend & Income Fund, Inc (see advisory)
2018-02-28 N-Q Prudential Investment Portfolios, Inc. (see advisory)
2017-12-29 N-Q Domini Investment Trust (see advisory)
2017-09-25 N-Q Western Asset Global Corporate Defined Opportunity Fund Inc. (see advisory)
2017-09-27 N-Q Pioneer Series Trust Vii (see advisory)
2018-03-01 N-Q Pimco Funds (see advisory)
2017-12-20 N-Q Mfs Series Trust Iii (see advisory)
2018-03-01 N-Q City National Rochdale Funds (see advisory)
2017-11-29 N-Q Delaware Vip Trust (see advisory)
2018-02-28 N-Q Sunamerica Income Funds (see advisory)
2018-01-29 N-Q Invesco High Income Trust Ii (see advisory)
2017-11-29 N-Q Lord Abbett Series Fund Inc (see advisory)
2018-01-25 N-Q Prudential Investment Portfolios, Inc. 15 (see advisory)
2017-11-27 N-Q Voya Investors Trust (see advisory)
2017-09-28 N-Q Aberdeen Global Income Fund Inc (see advisory)
2018-01-22 N-Q Blackrock Ltd Duration Income Trust (see advisory)
2017-09-27 N-Q Ab High Income Fund Inc (see advisory)
2017-10-30 N-Q Lord Abbett Investment Trust (see advisory)
2017-12-28 N-Q Prudential Global Short Duration High Yield Fund, Inc. (see advisory)
2017-11-29 N-Q Eaton Vance Floating-rate 2022 Target Term Trust (see advisory)
2017-12-22 N-Q Blackrock Funds (see advisory)
2018-01-22 N-Q Blackrock Corporate High Yield Fund, Inc. (see advisory)
2017-12-27 N-Q Delaware Group Income Funds (see advisory)
2017-10-27 N-Q Virtus Global Multi-sector Income Fund (see advisory)
2017-09-26 N-Q Voya Mutual Funds (see advisory)
2017-10-27 N-Q Western Asset Funds Inc (see advisory)
2017-09-26 N-Q Morgan Stanley Global Fixed Income Opportunities Fund (see advisory)
2017-09-27 N-Q Etfis Series Trust I (see advisory)
2017-09-25 N-Q Western Asset High Income Fund Ii Inc. (see advisory)
2018-02-27 N-Q Putnam Master Intermediate Income Trust (see advisory)
2017-09-29 N-Q Putnam Income Fund (see advisory)
2018-02-28 N-Q Morgan Stanley Institutional Fund Trust (see advisory)
2018-03-01 N-Q Oppenheimer Global Strategic Income Fund (see advisory)
2017-09-27 N-Q Blackrock Multi-sector Income Trust (see advisory)
2018-02-26 N-Q TIAA-CREF FUNDS (see advisory)
2017-11-28 N-Q Pimco Etf Trust (see advisory)
2017-11-24 N-Q Pioneer Variable Contracts Trust /ma/ (see advisory)
2017-12-21 N-Q American Pension Investors Trust (see advisory)
2018-01-25 N-Q Putnam High Income Securities Fund (see advisory)
2017-11-29 N-Q Lord Abbett Bond Debenture Fund Inc (see advisory)
2017-10-25 N-Q Western Asset Global High Income Fund Inc. (see advisory)
2018-03-01 N-Q Rivernorth Funds (see advisory)
2017-10-30 N-Q Oppenheimer Global High Yield Fund (see advisory)
2017-11-29 N-Q Eaton Vance Senior Income Trust (see advisory)
2017-09-29 N-Q John Hancock Investors Trust (see advisory)
2018-02-27 N-Q Putnam Diversified Income Trust (see advisory)
2017-12-28 N-Q Putnam Premier Income Trust (see advisory)
2018-02-28 N-Q Deutsche Income Trust (see advisory)
2017-09-29 N-Q Boston Income Portfolio (see advisory)
2017-11-27 N-Q Federated Core Trust/pa (see advisory)
2017-10-27 N-Q Eaton Vance Floating-rate Income Trust (see advisory)
2018-03-01 N-Q Calvert Fund (see advisory)
2017-09-27 N-Q Blackrock Credit Allocation Income Trust (see advisory)
2018-01-26 N-Q Jpmorgan Trust Iv (see advisory)
2017-12-28 N-Q George Putnam Balanced Fund (see advisory)
2018-01-29 N-Q Invesco Bond Fund (see advisory)
2017-11-29 N-Q Virtus Global Dividend & Income Fund Inc. (see advisory)
2017-09-28 N-Q Mfs Multimarket Income Trust (see advisory)
2017-09-29 N-Q Eaton Vance Nextshares Trust (see advisory)
2017-11-17 N-Q Nationwide Variable Insurance Trust (see advisory)
2017-12-27 N-Q Delaware Group Government Fund (see advisory)
2018-02-27 N-Q Pioneer Strategic Income Fund (see advisory)
2018-03-01 N-Q First Investors Income Funds (see advisory)
2017-12-27 N-Q Advisors' Inner Circle Fund Ii (see advisory)
2017-09-29 N-Q Putnam Global Income Trust (see advisory)
2018-03-01 N-Q Delaware Group Foundation Funds (see advisory)
2018-01-25 N-Q Federated High Yield Trust (see advisory)
2018-02-27 N-Q Massmutual Premier Funds (see advisory)
2017-10-27 N-Q Virtus Total Return Fund Inc. (see advisory)
2018-02-26 N-Q Ab Bond Fund, Inc. (see advisory)
2018-02-27 N-Q Northern Funds (see advisory)
2018-02-28 N-Q Guggenheim Funds Trust (see advisory)
2017-10-30 N-Q Delaware Enhanced Global Dividend & Income Fund (see advisory)
2018-03-01 N-Q Eaton Vance Ltd Duration Income Fund (see advisory)
2018-01-29 N-Q Aim Counselor Series Trust (invesco Counselor Series Trust) (see advisory)
2018-02-28 N-Q Steben Alternative Investment Funds (see advisory)
2018-02-27 N-Q Federated High Income Bond Fund Inc (see advisory)
2017-09-28 N-Q Delaware Group Adviser Funds (see advisory)
2017-11-28 N-Q Putnam Variable Trust (see advisory)
2018-02-28 N-Q Ivy Funds (see advisory)
2018-03-01 N-Q Sei Institutional Managed Trust (see advisory)
2017-12-22 N-Q Legg Mason Partners Income Trust (see advisory)
2018-01-22 N-Q Blackrock Debt Strategies Fund, Inc. (see advisory)
2017-11-24 N-Q Touchstone Variable Series Trust (see advisory)
2017-10-26 N-Q Mfs Charter Income Trust (see advisory)
2017-11-29 N-Q Investment Managers Series Trust (see advisory)
2017-10-26 N-Q Mfs Intermediate High Income Fund (see advisory)
2017-11-22 N-Q Mml Series Investment Fund Ii (see advisory)
2017-11-24 N-Q Pioneer Bond Fund /de/ (see advisory)
2017-11-29 N-Q Virtus Variable Insurance Trust (see advisory)
2017-12-28 N-Q Hartford Funds Exchange-traded Trust (see advisory)
2018-01-26 N-Q Pioneer Series Trust V (see advisory)
2017-09-27 N-Q Ab Unconstrained Bond Fund, Inc. (see advisory)
2018-02-28 N-Q Goldman Sachs Trust (see advisory)
2017-09-29 N-Q High Income Opportunities Portfolio (see advisory)
2017-12-29 N-Q Virtus Etf Trust Ii (see advisory)
2018-02-28 N-Q Virtus Opportunities Trust (see advisory)
2017-09-29 N-Q Eaton Vance Senior Floating Rate Trust (see advisory)
2017-10-30 N-Q John Hancock Bond Trust (see advisory)
2018-02-28 N-Q Pacific Funds Series Trust (see advisory)
2018-02-27 N-Q Putnam Asset Allocation Funds (see advisory)
2018-01-25 N-Q Putnam Funds Trust (see advisory)
2017-09-29 N-Q Dunham Funds (see advisory)
2018-03-01 N-Q Optimum Fund Trust (see advisory)
2018-02-26 N-Q Blackrock Funds Ii (see advisory)
2017-10-27 N-Q Putnam High Yield Fund (see advisory)
2018-02-27 N-Q Touchstone Funds Group Trust (see advisory)
2017-11-27 N-Q Federated Insurance Series (see advisory)
2017-09-28 N-Q Delaware Pooled Trust (see advisory)
2018-02-26 N-Q Western Asset High Income Opportunity Fund Inc. (see advisory)
2017-11-27 N-Q Voya Partners Inc (see advisory)
2017-09-28 N-Q Federated Institutional Trust (see advisory)
2017-11-22 N-Q General Electric Rsp Income Fund (see advisory)
2018-01-22 N-Q Blackrock Core Bond Trust (see advisory)
2018-02-28 N-Q State Street Institutional Funds (see advisory)
2017-11-22 N-Q Elfun Income Fund (see advisory)
2017-11-29 N-Q Professionally Managed Portfolios (see advisory)
2017-09-29 N-Q Global Income Builder Portfolio (see advisory)
2018-02-28 N-Q Virtus Equity Trust (see advisory)
2017-11-27 N-Q Voya Balanced Portfolio Inc (see advisory)
2018-01-25 N-Q Ab Portfolios (see advisory)

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.


  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( NSE:SIL / STANDARD INDUSTRIES LTD. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...